1. Scrip
  2. >>R&D

What Sanofi Early Research Chief Scientist Frank Nestle Is Most Excited About

Immunology And Oncology Pipelines Expanding

 
• By Jessica Merrill

Sanofi's Nestle talked to Scrip about the company's early pipeline, the emerging technologies he thinks are most promising and tapping external innovation.

Sanofi
Sanofi's Frank Nestle talked to Scrip about R&D • Source: Shutterstock

Sanofi's approach to drug discovery and early pipeline development has been changing over the last five years, and global head of research and chief scientific officer Frank Nestle said in an interview that some of the investment that has been put in is beginning to deliver promising new drug candidates.

"It's a science-led organization with a cultural drive, with a play-to-win attitude and a portfolio that is evolving but already...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Lilly’s Orforglipron Makes Strong Showing In Diabetic Obesity Population

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III ATTAIN-2 trial in overweight/obese patients with type 2 diabetes and plans to file for approval.

Regeneron Plans To File Cemdisiran For gMG But Will Face Tough Market

 
• By Jessica Merrill

Head of hematology clinical development Andres Sirulnik talked to Scrip about the positive Phase III results for the siRNA medicine.

Novartis Signs Up For BioArctic Blood-Brain Barrier Tech

 
• By Kevin Grogan

The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.

US FDA Suspends Valneva’s Ixchiq Based On Four New Serious AE Reports

 
• By Sue Sutter

After an Aug. 6 safety labeling change, the FDA became aware of “more compelling evidence” that the risk for serious chikungunya-like illness is not limited to older adults, CBER Director Prasad said.

More from Scrip

Stock Watch: Bloodbaths And Blood Letting At CSL And Bayer

 
• By Andy Smith

Financial announcements that report falling sales or profits may result in share price weakness, while big restructurings, or their extended continuation, can elicit protest votes from shareholders.

GSK India Oncology Second Innings: Can Jemperli, Zejula Set The Pace?

 
• By Anju Ghangurde

GSK recommits to oncology in India with the debut of Jemperli and Zejula, backed by a tiered pricing approach, patient support program and efforts to address unmet needs in the biomarker ecosystem. Can it widen treatment access materially?

US FDA Suspends Valneva’s Ixchiq Based On Four New Serious AE Reports

 
• By Sue Sutter

After an Aug. 6 safety labeling change, the FDA became aware of “more compelling evidence” that the risk for serious chikungunya-like illness is not limited to older adults, CBER Director Prasad said.